Digital Patient Support: The Evidence for Better Adherence

Medication adherence is one of the oldest problems in healthcare. Across chronic conditions, roughly half of all patients do not take their medications as prescribed — a figure that has remained stubbornly consistent for decades. GLP-1 receptor agonists are no exception. Despite their remarkable efficacy, real-world adherence and persistence data paint a sobering picture: a significant proportion of patients discontinue treatment within the first year.

The question for prescribers is not whether adherence matters — it clearly does — but what can actually be done about it. A growing body of evidence suggests that structured digital health interventions offer one of the most promising answers.

What the Evidence Shows

The research linking digital health interventions to improved medication adherence has matured considerably in recent years. A systematic review and meta-analysis by Xiong and colleagues, published in the Journal of Medical Internet Research in 2025, examined digital interventions across multiple chronic conditions and found consistent, statistically significant improvements in adherence compared to usual care. The effect sizes were modest individually but clinically meaningful at a population level — particularly when interventions combined multiple components such as reminders, monitoring, and educational content.

This aligns with earlier landmark work. Basch and colleagues, writing in JAMA in 2017, demonstrated that systematic collection of patient-reported outcomes (PROs) in oncology patients led to measurable improvements in clinical outcomes, including fewer emergency department visits and longer survival. While the disease context differs, the principle is directly transferable: when patients are actively monitored and their concerns are captured systematically, clinical teams can intervene earlier and more effectively.

The common thread across this evidence is structure. Ad hoc digital communication — a WhatsApp message here, an email there — does not reliably improve outcomes. What works is a systematic approach: regular data collection, predefined escalation pathways, and clinical workflows that act on the information gathered.

The Specific Challenge of GLP-1 Adherence

GLP-1 medications present particular adherence challenges. They are injectable, which creates an ongoing psychological barrier for many patients. They cause gastrointestinal side effects that, while usually transient, can be unpleasant enough to prompt discontinuation. They require dose escalation, which reintroduces side effects at each step. And they are typically self-funded in the private market, meaning patients are acutely sensitive to whether they are receiving value for their investment.

Real-world data consistently shows dropout rates of 30 to 50 per cent within the first six months of GLP-1 treatment. The reasons are predictable: unmanaged side effects, unmet expectations, lack of clinical support, and the feeling that no one is paying attention to their experience.

This is precisely the gap that structured digital support is designed to fill. By collecting patient-reported outcomes daily, prescribers can identify patients who are struggling — with nausea, with constipation, with inadequate weight loss, with injection anxiety — before those patients decide to stop treatment.

What “Structured” Actually Means

It is worth being precise about terminology. The digital health market is flooded with apps, platforms, and tools that claim to support patients. But the evidence distinguishes clearly between passive tools (calorie trackers, information libraries, generic reminder apps) and active, structured interventions.

Structured digital support, as defined in the adherence literature, typically includes several core components. First, regular and systematic data collection — not optional logging, but prompted check-ins that capture specific clinical parameters. Second, clinical review workflows that ensure the data is actually seen and acted upon by a healthcare professional. Third, predefined escalation criteria that flag patients requiring intervention. And fourth, closed-loop communication that confirms to the patient that their data has been received and reviewed.

The distinction matters because passive tools consistently underperform in adherence studies. Giving a patient an app and hoping they use it is not a digital health intervention — it is wishful thinking. The Cadence platform was designed around this distinction, building structured PRO collection and clinical escalation into the core workflow rather than treating them as optional features.

PRO Monitoring and Early Intervention

Patient-reported outcomes are the engine of effective digital adherence support. When patients report their symptoms, side effects, weight, and wellbeing on a regular basis, the resulting data stream gives prescribers something they have never had before: visibility into what happens between appointments.

In traditional models, a prescriber sees a patient every four to six weeks. If that patient experienced severe nausea during week two, struggled with constipation in week three, and stopped taking the medication in week four, the prescriber learns about it — if at all — after the damage is done.

With daily PRO monitoring, the nausea is flagged on day three. The constipation is identified in week two. The prescriber intervenes before the patient reaches the point of discontinuation. This shift from reactive to proactive care is arguably the single most important advancement in adherence management.

The Cadence dashboard visualises these patient-reported outcomes in real time, giving clinical teams a clear view of which patients are on track and which need attention — without requiring them to manually chase every patient.

Real-World Retention Data

While randomised controlled trial data on digital support specifically for GLP-1 adherence is still emerging, real-world evidence is encouraging. Found Health, a US-based digital weight management platform, reported 69 per cent patient retention at 12 months — substantially higher than the figures seen in typical clinical practice. Their model combines GLP-1 prescribing with structured digital support, including regular check-ins, behavioural coaching, and outcome tracking.

This data point is significant not because it represents definitive proof, but because it demonstrates what is achievable when prescribing is embedded within a structured support framework rather than delivered in isolation. The retention differential — potentially 20 to 30 percentage points above the baseline — translates directly into better patient outcomes and more sustainable clinic economics.

Implications for Prescribers

For GLP-1 prescribers evaluating their support model, the evidence points in a clear direction. Generic apps and passive tools are unlikely to meaningfully improve adherence. What works is structured, proactive, clinician-connected digital support that collects data systematically and acts on it promptly.

When choosing a platform or building a support workflow, prescribers should look for several features: daily or regular PRO collection, clinical dashboards that surface patients at risk, defined escalation pathways, and communication tools that maintain the patient-prescriber relationship rather than replacing it.

The evidence also favours proactive over reactive models. Waiting for patients to contact you with problems will always miss the patients who simply disengage silently. Proactive outreach — checking in before patients need to ask for help — is consistently associated with better retention and outcomes.

Moving From Evidence to Practice

The gap between evidence and practice in digital health remains wide. Many prescribers know that patient support matters but lack the tools or workflows to deliver it consistently. Others have invested in technology that collects data but provides no mechanism for acting on it.

Closing this gap requires platforms built specifically for the clinical context — not repurposed consumer wellness apps, but tools designed around the realities of GLP-1 prescribing, dose escalation, side effect management, and long-term weight management.

If you are looking to align your practice with the evidence on digital adherence support, book a demo to see how Cadence translates these principles into a practical clinical workflow. The research is clear: structured support works. The question is whether your service is set up to deliver it.